secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K/A
Filed at:   2025-04-03T23:59:59+00:00
Accession:  0001731122-25-000524
Event type: regulatory
Sentiment:  negative
Materiality: 1.00
Item codes: 3.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax receives Nasdaq delisting notice; all independent directors and CFO resign
--------------------------------------------------------------------------------

- Nasdaq panel delists Virpax for failing minimum stockholders' equity; trading suspended April 4, 2025.
- Company will not appeal; delisting effective after SEC Form 25 filing.
- Four directors (Randhawa, Deol, Su, Field) resigned effective April 2, 2025.
- Katharyn Field also resigned as VP; Usama Chaudhry resigned as CFO, same date.
- Resignations not due to any disagreement with company per filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000173112225000524/0001731122-25-000524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000173112225000524/e6490_8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001731122-25-000524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer